Kaida BioPharma was founded on the research principles and clinical evidence of G129R, a growth hormone antagonist that has shown to induce programmed cell death (autophagy) in gynecologic tumors. Our collaboration with Dr. John Langenheim, professor at Thomas Jefferson University and Dr. Anil Sood at MD Anderson, who have published extensive research on G129R, has provided solutions we intend to bring to the clinic. At Kaida, we are dedicated to providing a new hope for patients with treatment-resistant gynecological cancers. Our mission is to develop innovative therapies that target the specific needs of those patients, offering a medical treatment that can make a significant difference. For more information, please visit kaida-biopharma.com.
Company Details
- Employees
- 4
- Address
- The Urgent Need Of 90% Of Patients Seeking Effective Treatment.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.kaida-biopharma.com/
Kaida Biopharma Questions
Kaida Biopharma's website is https://www.kaida-biopharma.com/
Kaida Biopharma's LinkedIn profile is https://www.linkedin.com/company/kaida-biopharma
Kaida Biopharma has
4 employees.
View email and phone details for 4
employees at Kaida Biopharma.
Kaida Biopharma's industry is
Biotechnology Research
Kaida Biopharma's top competitors are
Imaginostics,
Likarda, Inc.,
Northway Biotech,
Oral Biolife Inc.,
Amend Surgical, Inc.,
Ziptek Llc,
Eder Therapeutics,
Snc Therapeutics, Inc.,
Vanquish Bio,
Azome Therapeutics.
Kaida Biopharma's categories are Biotechnology Research
